Takeda to close $62bn deal for Irish company Shire in January
Takeda investors are to hold an extraordinary general meeting as it prepares to seek approval for its $62 billion bid for the the Irish headquartered pharmaceutical organisation. It aims to have the deal closed by January 8th.
If the deal succeeds it would be the largest ever overseas acquisition by a Japanese company.
For the deal to succeed however it will need approval by two-thirds of its shareholders, some of whom have expressed concern about the way in which it will increase the pharma giants debt burden.
The deal is also pending EU approval from regulators but the deal would see Takeda move into the top 10 of global drugmakers by sales.